ProCore Bio Med
Cell and Tissue Regeneration Solutions
Company Overview
Snapshot
Founded in September 2008 by Prof. Avner Yayon, ProCore Bio Med operates with 1–10 employees. The company focuses on developing advanced solutions for cell and tissue regeneration, particularly in bone and cartilage repair, leveraging its proprietary biomaterials and growth factors.
Business overview
ProCore Bio Med is a biotechnology company specializing in cost-effective solutions for bone and cartilage regeneration. Its core technology platform integrates proprietary scaffolds, growth factors, and stem or progenitor cells, utilizing a variety of biomaterials, including hyaluronic acid-based injectable hydrogels. The company's flagship product, RegenoGel, is a viscosupplement gel designed for treating osteoarthritis to preserve joints and regenerate cartilage. ProCore Bio Med serves the healthcare and life sciences sectors, targeting providers with its medical technologies and biomaterials for therapeutic applications.
Company Intelligence Q&A
- What is ProCore Bio Med's primary focus?
- ProCore Bio Med develops cost-effective solutions for cell and tissue regeneration, with a particular emphasis on bone and cartilage repair.
- Who founded ProCore Bio Med?
- ProCore Bio Med was founded by Prof. Avner Yayon in September 2008.
- What is RegenoGel?
- RegenoGel is ProCore Bio Med's highly stable viscosupplement gel designed for treating osteoarthritis to preserve joints and regenerate cartilage. It is based on the company's proprietary HAProLink technology.
- What kind of technology platform does ProCore Bio Med utilize?
- ProCore Bio Med's technology platform includes various biomaterials, such as hyaluronic acid-based injectable hydrogels, proprietary growth factors with enhanced activity, and protocols for stem and progenitor cell isolation, expansion, and differentiation.
- What role did ProCore Bio Med play in the Genesis consortium?
- ProCore Bio Med was a principal member of the Genesis consortium, the Israeli consortium for stem cell therapy. The company contributed its proprietary set of FGF variants, its unique stem cell platform, and developed a novel antibody microarray for stem cell characterization.